Last reviewed · How we verify
IDP-126 Vehicle Gel
IDP-126 is a topical gel formulation designed to deliver active pharmaceutical ingredients to treat dermatological conditions.
IDP-126 is a topical gel formulation designed to deliver active pharmaceutical ingredients to treat dermatological conditions. Used for Dermatological conditions (specific indication not publicly disclosed).
At a glance
| Generic name | IDP-126 Vehicle Gel |
|---|---|
| Also known as | Vehicle |
| Sponsor | Bausch Health Americas, Inc. |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
IDP-126 Vehicle Gel is a phase 3 topical formulation developed by Bausch Health Americas. As a vehicle gel, it serves as the delivery system for active ingredients in dermatological applications. The specific mechanism depends on the active pharmaceutical ingredient incorporated into the gel matrix.
Approved indications
- Dermatological conditions (specific indication not publicly disclosed)
Common side effects
Key clinical trials
- Study to Compare the Safety and Efficacy of IDP-126 Gel to Epiduo® Forte Gel and Vehicle Gel (PHASE2)
- Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris (PHASE3)
- Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris (PHASE3)
- A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IDP-126 Vehicle Gel CI brief — competitive landscape report
- IDP-126 Vehicle Gel updates RSS · CI watch RSS
- Bausch Health Americas, Inc. portfolio CI